Next-generation sequencing in myeloproliferative malignancies: financial considerations in Polish context

In this study, we assessed a number of factors influencing the cost of Sanger sequencing and next-generation sequencing (NGS), including patient population and indications for genetic testing, reimbursement status of the described procedures, and material and personnel costs based on the example of the Department of Hematology and Genetic Diagnostics at The University Hospital in Krakow, Poland. We discuss the advantages and disadvantages of the innovative technology used for routine genetic diagnostics of patients in relation to the latest World Health Organization guidelines. As understanding of the genetic basis of diseases expands, and the range of available diagnostic methods increases, the cost of genetic testing continues to rise. This trend includes diagnostic tests based on NGS technology, which is constantly evolving to offer an increasingly broad range of studies of changes to the genome. Therefore, the challenge for healthcare funders is to ensure that reimbursement is commensurate with the capabilities of modern diagnostics, and that a lack of funding does not inhibit the ability to provide optimal care to patients.